CHRISTOPH ZIELINSKI was named editor-in-chief of ESMO Open, a new open-access, peer-reviewed online journal published by the European Society of Medical Oncology.
ROBERT SCHREIBER and PHILIP GREENBERG were named editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the American Association for Cancer Research.
DAN JONES and ANIL PARWANI were recruited to serve in leadership roles for specialized pathology services offered across The Ohio State University Wexner Medical Center.
MD ANDERSON CANCER CENTER and Esperance Pharmaceuticals Inc. entered into a strategic alliance to accelerate the clinical development of its lead anti-cancer candidate, EP-100, for the treatment of ovarian cancer, and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.
ROBIN DAVISSON was named president and CEO-elect of the Melanoma Research Alliance effective Oct. 1.
BROAD INSTITUTE and MD ANDERSON CANCER CENTER were designated the Genome Characterization Centers in a five-year project supported by the NCI to characterize the genomic changes found in tumors.
CHAD MIRKIN was named the inaugural recipient of the Raymond and Beverly Sackler Prize in Convergence Research by the National Academy of Sciences.
TROVAGENE INC. established the Trovagene Research Institute, a European subsidiary focused on expanding the capabilities and adoption of the company's Precision Cancer Monitoring platform. Trovagene has also entered into a collaboration with the Department of Oncology at the University of Torino.
HERBERT FRITSCHE received the 2015 Abbott Award from the International Society of Oncology and Biomarkers for contributions to the field of basic or clinical oncology.
CARLOS ARTEAGA and FREDERICK ALT were named the winners of the 2015 Prize for Scientific Excellence by the American-Italian Cancer Foundation.
